When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MGNX - MacroGenics' first product Ok'd by the FDA for breast cancer
MacroGenics Inc.
The FDA has approved MacroGenics' (MGNX) Margenza (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens,Matgenza is the first product approved from MacroGenics’ pipeline.Product launch is anticipated in March of 2021.Conference call is scheduled for tomorrow at 8:00 a.m. ET.